Dr. Emer Leahy received her Ph.D. in Neuropharmacology at University College Dublin, Ireland and her MBA from Columbia University. She has more than 20 years of behavioral research experience, as well as, experience in business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions and strategic planning. Dr. Leahy has spearheaded contract negotiations and licensing agreements focusing on Alzheimer’s disease, psychiatry, epilepsy and other neuro-degenerative disorders. Dr. Leahy serves on the Board of Directors of Psylin NeuroSciences where she also acts as Co-CEO. She was recently elected to the Board of Directors of the Biotechnology Industry Organization (BIO), and serves on its Emerging Companies Section Governing Board.

Dr. David Lowe most recently served as CSO and a member of the Board of Directors at Memory Pharmaceuticals, (acquired by Hoffman-La Roche Inc). Prior to that, he served as Executive Vice President and Chief Scientific Officer of Fidelity Biosciences and as the President and Chief Executive Officer of EnVivo Pharmaceuticals Inc. Dr. Lowe has held senior Neuroscience R&D positions in three large pharmaceutical companies, including Sandoz Ltd (now Novartis), Bayer AG, and Roche Bioscience, where he served as the Vice President and Therapeutic Area Head, CNS. Dr. Lowe has more than 25 years of experience in pharmaceutical drug discovery and product development, initiating and implementing collaborations with Pharma, Biotech, and academia, and an established track record of generating diverse clinical candidates.

Mr. Bill Fasnacht is a CPA with more than 25 years of experience in corporate finance and operations. Prior to joining PsychoGenics, Mr. Fasnacht served as Vice President of Finance, Worldwide Consumer Medicines and Vice President of Finance, Central and Eastern Europe for Bristol-Myers Squibb Company.

Mr. Mark Hofer has more than 25 years of experience in intellectual property and technology law. Prior to joining PsychoGenics, he was a partner at Brown, Rudnick, Berlack & Israels, where he initiated creation of the Intellectual Property Group. Mr. Hofer also served as General Counsel and Chief Patent Counsel for Genzyme Corporation and patent counsel for Johnson & Johnson. He is a member of the NY, NJ, MA and US Patent Bars.

Dr. Daniela Brunner received a Ph.D. in Experimental Psychology at Cambridge University, England. She is Adjunct Assistant Professor of Psychiatry at both Columbia and Yale Universities and possesses more than 20 years of behavioral research experience, including many years devoted to the development of mathematical models of behavior and information processing in animals.

Ms. Bavani Shankar received her M.B.A. at Columbia University, New York and her B.S. in Engineering in India. Ms. Shankar brings over 18 years domestic and international experience working in the pharmaceutical, biotechnology, specialty pharma and chemical industries. Most recently, Ms. Shankar was employed at Emisphere Technologies where she was Director of Corporate Development responsible for deal structure and negotiation for all in-licensing and out-licensing activities and strategic alliances.

Dr. David Pushett received his Ph.D. from Monash University, Australia. He is a founder of MindGenix, a company in transgenic research focused on Alzheimer’s disease and served as that company’s Chief Operations Officer. Dr. Pushett brings more then a decade of biotech research and business experience to PsychoGenics, including an extensive knowledge of CNS technology assessment, contract negotiations and strategic planning.

Dr. Hanania received her Ph.D. in Pharmacology at the University of Texas Medical Branch, Galveston. She completed her post doctoral training and was a faculty member of Department of Pharmacology at the University of Colorado Health Sciences Center. Dr. Hanania has extensive pharmacology and behavior experience in all neuropsychiatric areas and has been instrumental in establishing and validating many of PsychoGenics' behavioral tests.

Dr. Berend Olivier, former Vice President of Research for PsychoGenics, is currently Director of European Operations. He is Chairman and Professor of the Department of Psychopharmacology, Faculty of Pharmacy, at Utrecht University, The Netherlands and Adjunct Professor of Psychiatry at Yale University School of Medicine. Dr. Olivier is Former Head of CNS Research for Solvay Pharmaceuticals. He is also a member of PsychoGenics' Scientific Advisory Board.

Dr. Vadim Alexandrov received his Ph.D. in Quantum Chemistry from the University of Arizona and a subsequent Ph.D. in BioInformatics from Yale University. He has more than 15 years of experience in computational chemistry and bioinformatics. Dr. Alexandrov also has years of industry experience having worked as a Senior Bioinformatics Scientist at Curagen Corporation and as a Senior Infor-matics Consultant for Sanofi-Aventis Pharmaceuticals.

Dr. Sylvie Ramboz received her Ph.D. in Neurophar-macology at the Institute for Genetics and Cellular and Molecular Biology, Strasbourg, France. Dr. Ramboz has extensive experience in the biotechnology industry, first at Memory Pharmaceuticals, then at Xenogen Biosciences Corporation before joining PsychoGenics. While at Xenogen, she was responsible for creating and phenotyping more than 70 transgenic mouse models of CNS and sexual function disorders.

Ms. Christina Leahy has more than 20 years of laboratory experience in the pharmaceutical and biotechnology industries, including extensive knowledge of AAALAC and IACUC procedures and Federal regulatory and compliancy requirements. Prior to joining PsychoGenics, Ms. Leahy served as Quality Assurance Auditor for a Ciba-Geigy (now Novartis) GLP toxicology lab. At Bristol-Myers Squibb, she worked on in vivo testing for CNS drug discovery.

Dr. Ghavami obtained his Ph.D. in Neuroscience, from Universite de Louis Pasteur in Strasbourg, France, in conjugation with Columbia University. After receiving his Ph.D., he joined Memory Pharmaceuticals as Research Scientist. In May 2000, Afshin joined Wyeth's CNS subdivision where he led, evaluated and set up assays for several drug discovery programs including PDE4, RGS, and various GPCR receptors.